Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf333e4fc2ddf96d6d6077f516f8830e |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
filingDate |
2003-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e9fefe571f6b6a80fd47994945fe4624 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3508c132ee6a9f416dba1986eb65f307 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e38807d0debb97b52cbc5ced770d28b |
publicationDate |
2004-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2004109846-A1 |
titleOfInvention |
Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
abstract |
Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by restoring inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent is preferably a biologic agent such as an interleukin. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10485764-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10517886-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10519190-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007114697-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010093614-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2389930-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007117776-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012087234-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004052864-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9913856-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3238726-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10456415-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10858386-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11058705-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9839674-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004224919-A1 |
priorityDate |
2001-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |